 |
Top 10 Lymphoma and Myeloma treatment startups
Updated: April 19, 2024 |
These startups develop new Lymphoma and Myeloma treatments and diagnostics
technologies, like genome analysis, immunotherapy, gene therapy...
1
Country: USA | Funding: $1.2B
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
2
Country: USA | Funding: $335.4M
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Acquired by Gilead Sciences
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Acquired by Gilead Sciences
3
Country: USA | Funding: $310M
Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.
Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.
4
Country: USA | Funding: $215.1M
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, we are well positioned in an exciting new era of immuno-oncology.
5
Country: USA | Funding: $156M
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
6
Country: China | Funding: $101.6M
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
7
Country: USA | Funding: $98M
LAM Therapeutics develops drugs for rare diseases and cancer.
LAM Therapeutics develops drugs for rare diseases and cancer.
8
Country: USA | Funding: $75M
OncoMyx Therapeutics develops oncolytic immunotherapies to orchestrate an immune response and treat cancer.
OncoMyx Therapeutics develops oncolytic immunotherapies to orchestrate an immune response and treat cancer.
9
Country: Switzerland | Funding: $65.7M
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
10
Country: USA
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.
11
Country: USA | Funding: $33.9M
A discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
A discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.